These strategies operate by either inhibiting the TNF-alpha/TNFR1 pathway or disrupting the RIPK1-RIPK3-MLKL signaling cascade, thereby limiting vascular adaptability and preventing tumor recurrence. Here, TNFRSF1A is linked to neoplasm.